You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Rhinology
On demand events

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

Presentation highlights from the ADVENT symposium on disease remission in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.
Peter Hellings
Eugenio De Corso
MD, PhD
Peter Hellings +1 more

On demand materials

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
Rhinology
expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective
Rhinology
expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Rhinology
expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

What proportion of patients can achieve control in CRSwNP?
Rhinology
expert video

What proportion of patients can achieve control in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Rhinology
expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

When is the right time to consider a biologic in patients with CRSwNP?
Rhinology
expert video

When is the right time to consider a biologic in patients with CRSwNP?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Rhinology
expert video

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

Learning objectives

  • Identify hallmarks of disease control in CRSwNP
  • Set appropriate goals beyond symptom control of patients with CRSwNP
  • Evaluate recently published definitions of remission in CRSwNP with an eye toward improving patient outcomes

Description

Join Dr. Shigeharu Fujieda, Prof. Peter Heilings, and Prof. Eugenio De Corso as they explore disease control and the emerging concept of disease remission in CRSwNP.

Tags
expert insightsstandard of caredisease controlremissionnasal obstructionloss of smell
MAT-GLB-2401111 - 1.0 - 05/2024

About these experts

Rhinology
MD, PhD

Peter Hellings

Professor and Clinic Head of the Department of Otorhinolaryngology | University Hospitals of Leuven, Belgium

Rhinology
MD, PhD

Eugenio De Corso

Adjunct Professor of Otorhinolaryngology | Catholic University of the Sacred Heart, Milan, Italy

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region